The annual survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly. Photo via Getty Images

Few studies gauge the barometric pressure of the Bayou City like the Kinder Houston Area Survey.

Designed to take the temperature of the general population, the study — now in its 40th year — reveals a Houston citizenry optimistic about its personal futures, per the report.

A little about the study before delving in: The report was conducted by the esteemed Stephen Klineberg, founding director of Rice University's Kinder Institute for Urban Research and emeritus professor of sociology; and Robert Bozick, senior research fellow at the Kinder Institute.

This new survey was unveiled at the Kinder Institute's "Lunch-Out" recent virtual event. Interviews of some 1,051 Harris County adults were conducted between January 18 and March 29 by the National Opinion Research Center at the University of Chicago.

The full report is available online.

The No. 1 concern

Public health concerns, while rarely registering in previous surveys, were cited as the biggest problem facing Houstonians this year, according to a press release. Some 25 percent of respondents cited the pandemic or health-related issues.

Others — 20 percent — pointed to the economy as the biggest problem, that's up from 13 percent last year. Only 14 percent cited crime, and traffic dropped to 13 percent, down from 30 percent last year.

Highlighting a national socioeconomic disparity, 58 percent of Blacks and 66 percent of Hispanics said they had to risk exposure to the coronavirus to keep their jobs during the past year, per the report. That's compared to 41 percent of Asians and only 36 percent of whites.

Additionally, the report notes that Blacks and Hispanics were more likely (at 73 percent and 67 percent, respectively) to know someone who was hospitalized with or died as a result of having COVID-19, compared with whites (57 percent) and Asians (40 percent).

Mental health issues have arisen as a serious problem in equal numbers across ethnic communities. More than 50 percent of respondents — in all four groups — reported feeling more stress and experiencing more emotional problems during the past year, compared with 2020.

Jobs and the economy

Though Houston is an opportunity city, the Kinder Survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly, to 61 percent this year from 68 percent in 2020.

A mere 21 percent reported their economic situations were getting better, down from 34 percent in 2020. Notably — for the first time in the 40 years — of the survey, more respondents (25 percent) said their financial situations were getting worse than getting better.

Blacks and Hispanics were also more likely than Asians and whites to have experienced a loss of income and to have received help from government programs in the past year.

Race relations, immigration, and inequity

Positive ratings of relations among ethnic groups in the Houston area declined across the board, especially among Blacks. Whites and Hispanics were significantly more likely than in previous years to agree that Blacks are still a long way from having the same opportunities in life as whites.

The number of people who said the criminal justice system is biased against Blacks increased to 54 percent from 32 percent in 2015, when the question was last asked, per a release.

Weather, religion, and politics

Area residents were less likely than in previous surveys to say it's virtually certain the region will experience more severe storms in coming years (59 percent in 2021, compared with 81 percent in 2018 and 2020).

The number of religious Houstonians continues to decline, with more people than ever indicating they are not part of any faith tradition (22 percent today, compared with 8 percent in 2008) and do not consider religion to be an important part of their lives (26 percent, compared with 10 percent in 2008), per the study.

Meanwhile, 45 percent of those surveyed said they felt closer to the Democratic Party this year, while only 25 percent voiced support for the Republican Party.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.